Friday, 26 April 2024
Concert Pharmaceuticals Inc.
NASDAQ : CNCE
6.070 14 Oct 22 00:00 | Change: 0.19 | Open: 6.240 | High: 6.340 | Ask: 0.000 | Volume: 278,900 |
Change(%): 3.04 | Prev: 6.260 | Low: 6.050 | Bid: 0.000 | Avg vol: 0 |
13:00 | 5/2/18
Dispatch Tribunal
Concert Pharmaceuticals (NASDAQ:CNCE) last released its earnings results on Thursday, November 9th. The biotechnology company reported ($0.70) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.54) by ($0.16 ...
more»
No Risk Alert Here: Before we dive into any analysis we simply note that Concert Pharmaceuticals Inc (NASDAQ:CNCE) risk is neither elevated nor depressed.
more»
02:18 | 12/1/18
Concord Register
Concert Pharmaceuticals, Inc. (NasdaqGM:CNCE) has an ERP5 rank of 6624. The ERP5 Rank is an investment tool that analysts use to discover undervalued companies.
more»
12:15 | 11/1/18
The Ledger Gazette
Zacks Investment Research raised Concert Pharmaceuticals from a “hold” rating to a “buy” rating and set a $16.00 target price on the stock in a research report on Tuesday, September 26th.
more»
16:00 | 1/1/18
The Ledger Gazette
Concert Pharmaceuticals logo Prudential Financial Inc. decreased its stake in shares of Concert Pharmaceuticals Inc (NASDAQ:CNCE) by 34.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission.
more»
There are currently no comments on this topic.
Be the first person to Add a Comment...
You must be a registered user to post a comment: REGISTER NOW
If you are already registered, please LOGIN NOW
|
Code | Last | Change |
COMP | 10,321 | 328 | | 3.08% |
DJI | 29,635 | 404 | | 1.34% |
SP500 | 3,583 | 87 | | 2.37% |
DAX | 12,438 | 82 | | 0.67% |
FTSE | 7,488 | 5 | | 0.07% |
NI225 | 22,420 | 408 | | 1.86% |
TWI | 67.27 | 0.00 | | 0.00% |